Preclinical News and Research

RSS

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

Nanobiotix has announced that an independent preclinical study has validated the applicability of using its nanoparticles-nanoPDT-to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology.

6 Apr 2009

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

2 Apr 2009

FDA clears Cellectar's IND application for drug candidate

Cellectar, Inc., a privately held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its (131)I-CLR1404 drug candidate for testing in patients with advanced solid malignancies.

2 Apr 2009

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

CeNeRx BioPharma, Inc. has announced issuance of a new U.S. patent covering its novel compounds that selectively target peripheral cannabinoid receptors.

1 Apr 2009

Researchers develop mouse models of leukemia that predict response to chemotherapy

Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment.

1 Apr 2009

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

1 Apr 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE).

30 Mar 2009

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Researchers develop system to culture normal and cancerous pancreatic tissue isolated from resection specimens obtained from patients

Pancreatic cancer is a devastating disease with a very poor prognosis.

24 Mar 2009

Gold nanoparticles "cook" cancer cells

Researchers are describing a long-awaited advance toward applying the marvels of nanotechnology in the battle against cancer.

22 Mar 2009

Hollow gold nanospheres show promise in cancer therapy

A new metal nanostructure developed by researchers at the University of California, Santa Cruz, has already shown promise in cancer therapy studies and could be used for chemical and biological sensors and other applications as well.

22 Mar 2009

New TB vaccine developed using a genetically modified adenovirus

McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

20 Mar 2009

Novel stimulation method sparks hope for Parkinson's disease sufferers

A novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, may offer an effective and less invasive approach for Parkinson's disease treatment, according to pre-clinical data published in the journal Science by researchers at Duke University Medical Center.

20 Mar 2009

Synthesizing Vernix caseosa

Even after nine months soaking in the womb, a newborn's skin is smooth - unlike an adult's in the bath.

17 Mar 2009

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Arno Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-42.

17 Mar 2009

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Preliminary research in healthy men suggests that the narcolepsy drug modafinil, increasingly being used to enhance cognitive abilities, affects the activity of dopamine in the brain in a way that may create the potential for abuse and dependence, according to a study in the March 18 issue of JAMA.

17 Mar 2009

Preclinical News and Research

Nanobiotix reports 'proof of concept' for use of nanoparticles in treating glioblastoma multiforme

FDA provides positive review of InNexus Biotechnology development plan for lead preclinical candidate

FDA clears Cellectar's IND application for drug candidate

CeNeRx BioPharma awarded patent for novel compounds that selectively target peripheral cannabinoid receptors

Researchers develop mouse models of leukemia that predict response to chemotherapy

By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Orexo reports on efficacy study in allergic rhinitis with OX914

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Researchers develop system to culture normal and cancerous pancreatic tissue isolated from resection specimens obtained from patients

Gold nanoparticles "cook" cancer cells

Hollow gold nanospheres show promise in cancer therapy

New TB vaccine developed using a genetically modified adenovirus

Novel stimulation method sparks hope for Parkinson's disease sufferers

Synthesizing Vernix caseosa

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News